Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short term Debt (2020 - 2022)

Historic Short term Debt for Arcturus Therapeutics Holdings (ARCT) over the last 3 years, with Q4 2022 value amounting to $60.7 million.

  • Arcturus Therapeutics Holdings' Short term Debt rose 16988.97% to $60.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $60.7 million, marking a year-over-year increase of 16988.97%. This contributed to the annual value of $60.7 million for FY2022, which is 16988.97% up from last year.
  • As of Q4 2022, Arcturus Therapeutics Holdings' Short term Debt stood at $60.7 million, which was up 16988.97% from $27.7 million recorded in Q3 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Short term Debt peaked at $60.7 million during Q4 2022, and registered a low of $1.2 million during Q4 2020.
  • For the 3-year period, Arcturus Therapeutics Holdings' Short term Debt averaged around $21.1 million, with its median value being $22.5 million (2021).
  • Its Short term Debt has fluctuated over the past 5 years, first surged by 169792.0% in 2021, then soared by 4988.64% in 2022.
  • Quarter analysis of 3 years shows Arcturus Therapeutics Holdings' Short term Debt stood at $1.2 million in 2020, then soared by 1697.92% to $22.5 million in 2021, then soared by 169.89% to $60.7 million in 2022.
  • Its Short term Debt was $60.7 million in Q4 2022, compared to $27.7 million in Q3 2022 and $27.0 million in Q2 2022.